- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-01-01-2022
Keeping Tabs on Quality: The Rise of Digital
January 11, 2022
Features
42
1
Industry experts convene for discussion on new quality management systems.
China Invests in Building Biotech
January 11, 2022
Features
42
1
Government-led programs aim to attract scientists and offer resources to growing industry.
Branding Takes on a New Look
January 11, 2022
Features
42
1
Pharma moves beyond promoting products to increase recognition of company names.
Addressing Access Burdens
January 11, 2022
Features
42
1
Employer-sponsored health plans create an increasingly cloudy path to access.
Meeting the Patient—Virtually
January 11, 2022
Features
42
1
Standard for reaching patients shifts with influx of new technology in post-COVID world.
The Age of Influence
January 11, 2022
Features
42
1
Pandemic lockdowns push pharma into brand-new era of social engagement.
Boosting Immunotherapies
January 11, 2022
Features
42
1
Oncology and rare disease are ready to reap the benefits of COVID drug development.
Pharma’s Psychedelic Experience
January 11, 2022
Features
42
1
Growing evidence supports psychoactive substances can successfully treat mental issues.
Supply Chain Procurement
January 11, 2022
Features
42
1
As borders shut down during the pandemic, pharma learned some lessons about sourcing.
Our View on 2022: Pharm Exec’s Annual Industry Outlook
January 11, 2022
42
1
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.
Breaking New Ground in Biopharma
January 11, 2022
Executive Profile
42
1
Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.
Biopharma Reaches New Heights as Calendar Turns
January 11, 2022
Finance
42
1
Brief summary of EY’s 2022 M&A Firepower report highlights trends.
Empowered Patients Demand Digitalization, Make Mark on Pharma
January 11, 2022
Marketing
42
1
Need for greater transparency and access fuels Big Tech’s presence.
The Importance of Data Management in Taking Care of Business
January 11, 2022
Technology
42
1
The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.
Too Many ‘Chiefs’ or Are Execs Simply Getting Their Due?
January 11, 2022
Leadership
42
1
Questions grow over adding titles to the biopharma C-suite.
Europe Searches for Better Collaboration Across Regulators
January 11, 2022
Global Report
42
1
Looks to address disconnect between registration and reimbursement.
Major Challenges Lie Ahead for FDA and Biopharma
January 11, 2022
Washington Report
42
1
Progress in 2022 will require nimble action across several fronts.
Pharmaceutical Executive, January 2022 Issue (PDF)
January 11, 2022
Issue PDF
42
1
Click the title above for a link to open the Pharmaceutical Executive January 2022 issue in an interactive PDF format.
Escaping the “Valley of Death:” The Funding Process for Biotechnology Companies
January 04, 2022
Back Page
42
1
Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.